DIPG-10. A Phase I trial of panobinostat following radiation therapy in children with diffuse intrinsic pontine glioma (DIPG) or H3K27M-mutated thalamic diffuse midline glioma (DMG): Report from the Pediatric Brain Tumor Consortium (PBTC-047)

INTRODUCTION: Panobinostat is an oral HDAC inhibitor with pre-clinical activity against DIPG. The phase I study in children with progressive DIPG (stratum 1) defined the maximum-tolerated dose (MTD) as 10 mg/m(2) administered 3x/week, 3 weeks on/1 week off. Herein, we report results of stratum 2, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Monje, Michelle, Cooney, Tabitha, Glod, John, Huang, Jie, Baxter, Patricia, Vinitsky, Anna, Kilburn, Lindsay, Robison, Nathan J, Peer, Cody J, Figg, William D, Fouladi, Maryam, Fangusaro, Jason, Onar-Thomas, Arzu, Dunkel, Ira J, Warren, Katherine E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Diffuse Midline Glioma/DIPG
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164905/
http://dx.doi.org/10.1093/neuonc/noac079.067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164905/
http://dx.doi.org/10.1093/neuonc/noac079.067

Ejemplares similares